Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 299 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Osteoarthritis, Spine Clear all
Not yet recruiting Phase 4 Interventional

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

NCT07770646
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA)
Interventions
Secukinumab (IL-17i ), Upadacitinib (JAKi)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

NCT01087788
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 14, 2026, 4:59 PM EDT
Completed No phase listed Observational

Progression of Spinal Fusion in Ankylosing Spondylitis

NCT00085995
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional

Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis

NCT00090129
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Onercept, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
37
States / cities
Little Rock, Arkansas • Fresno, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 14, 2026, 4:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Not applicable Interventional

Stepping Up For Inflammatory Arthritis

NCT02912221
View directory record Official record
Conditions
Arthritis, Psoriatic, Arthritis, Rheumatoid
Interventions
Incentive
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Chronic Pain From Arthritis

NCT03008590
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 14, 2026, 4:59 PM EDT
Active, not recruiting Phase 4 Interventional

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
38
States / cities
Avondale, Arizona • Chandler, Arizona • Mesa, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

NCT01209702
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
tocilizumab, Placebo
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Huntington Beach, California • Aventura, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

NCT01118728
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 14, 2026, 4:59 PM EDT
Active, not recruiting Not applicable Interventional

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

NCT05715463
View directory record Official record
Conditions
Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Interventions
Resource sheets, Community Resource Specialist, Nurse Navigator
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis

NCT03783026
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Santa Monica, California • Upland, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

NCT03104374
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
72
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 14, 2026, 4:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Fontana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Web-based Support to Manage Arthritis Pain

NCT01463189
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Interventions
painACTION: Arthritis
Behavioral
Lead sponsor
Inflexxion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

NCT03347110
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 14, 2026, 4:59 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

NCT01209689
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Huntington Beach, California • Aventura, Florida • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 14, 2026, 4:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Ankylosing Spondylitis

NCT00081562
View directory record Official record
Conditions
Spondylitis, Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

NCT00265096
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
golimumab, Placebo; golimumab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Huntsville, Alabama • La Jolla, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 14, 2026, 4:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis

NCT00001375
View directory record Official record
Conditions
Arthritis, Arthritis, Reactive, Arthritis, Rheumatoid, Reiter's Disease, Synovitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)

NCT01198509
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
Interventions
doxycycline, vancomycin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 14, 2026, 4:59 PM EDT
Withdrawn Early Phase 1 Interventional

Terbinafine Treatment of Axial Spondyloarthropathy

NCT05119712
View directory record Official record
Conditions
Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis, Spondylitis Secondary to Inflammatory Bowel Disease, Axial Spondyloarthopathy
Interventions
Terbinafine Tablets, Laboratory Testing
Drug · Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Results available

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

NCT02154425
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions
Breast milk sampling, Certolizumab Pegol
Procedure · Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 14, 2026, 4:59 PM EDT